The application for the renewal of the approval of the active substance Trichoderma atroviride strain T-11 was submitted on 29 April 2016 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 27 May 2016 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority. On 31 March 2021, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on them between 11 August and 10 October 2021. On 13 June 2022, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 13 July 2022 within the deadline given. The Authority estimates that it will be able to finalise its conclusion for Trichoderma atroviride strain T-11 by the end of October 2026, and as the Commission will need time to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 14 months, until 31 January 2028.
Recital 37, Regulation (EU) 2026/2348
In force
- celex=32012R0844